Dr. Thomas A. Ollila, MD

Dr. Ollila practices at Rhode Island Hospital/Hasbro Children's in Providence, Rhode Island.

Dr. Ollila's NPI, 1184984049, was assigned on May 24, 2012. Dr. Ollila holds Rhode Island license MD14929.

Dr. Ollila's primary practice is Rhode Island Hospital/Hasbro Children's, at 593 Eddy St, Providence, RI 02903 in Providence County. The practice phone is (401) 444-6966.

Dr. Ollila's primary practice is Rhode Island Hospital/Hasbro Children's in Providence, Rhode Island. Dr. Ollila is also affiliated with The Miriam Hospital. The medical group on file is Rhode Island Hospital. Dmand AI also links Dr. Ollila to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ollila practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ollila's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ollila is licensed in Rhode Island.

CMS data shows 329 Medicare services from Dr. Ollila across 6 procedure codes in 2024, for 181 Medicare patients. Medicare paid $23,107 for them.

CMS counts 181 Medicare patients who saw Dr. Ollila in 2024. The largest group is 75 to 84, with 76 patients. 73% of them have high cholesterol, and 70% have high blood pressure. 11% are also on Medicaid. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ollila's median patient age at 74, with 46% women.

In 2024, Dr. Ollila wrote 520 Medicare Part D claims for 87 patients. 55% of them were for generic drugs. CMS names the drug for 383 of them, across 15 drugs with 11 or more claims each, at $1,800,102 in total drug cost. In 2023, CMS named 309 claims across 14 drugs.

Dr. Ollila accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ollila as offering telehealth.

Dmand AI links 37 papers to Dr. Ollila, published from 2016 to 2025. 2023 was the busiest year, with 5. The most frequent topics are Lymphoma, Large B-Cell, Diffuse, Immunotherapy, Adoptive and Receptors, Chimeric Antigen. Dr. Ollila has published most often in Blood Adv. Dr. Ollila's most frequent co-authors are Reem Md Karmali, MD, Kevin Andrew David, MD and John L. Reagan, MD.

CMS Open Payments shows 36 general payments to Dr. Ollila from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 87% of the total. ADC Therapeutics America, Inc. paid the most, $12,103.